|
|
|
Stem Cell Related Patent Number US6800616
| Title: | Treatment of HIV infections | | Inventors: | Wrenn, Jr., Simeon M.; Danville, CA, USA | | Summary: | Described herein is a method of treating infection of the human immunodeficiency virus (HIV). The invention relates to a process of administering to an HIV-infected host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Further disclosed is a method of treating an HIV-infected host via the administration of a highly active antiretroviral therapy; along with coadministration to the host of a therapeutic agent described herein. Also provided is a method of ex vivo or in vitro treatment of blood-derived cells, bone marrow transplants, or other organ transplants accordingly. | | Abstract: | Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of ex vivo or in vitro treatment of blood derived cells, bone marrow transplants, or other organ transplants including treating the blood derived cells, bone marrow transplants, or other organ transplants with a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Kits and compositions useful in the practice of the invention are also disclosed. | | US Patent Website: | Click Here for Full Text of Patent | | Title Number: | US6800616 | | Application Number: | US1998000032881 | | Date Filed: | 26/02/1998 | | Date Published: | 05/10/2004 | | Assignee: | SuperGen, Inc., Dublin, CA, USA |
|
|
